Trial · NCT01337986
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores | Group B: Dalfampridine | -0.04 | Standard Deviation 0.02 | LogMAR Score | |
| Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores | Group B: Placebo | -0.06 | Standard Deviation 0.02 | LogMAR Score | |
| Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores | Group A: Placebo | -0.08 | Standard Deviation 0.02 | LogMAR Score | |
| Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores | Group A: Dalfampridine | -0.06 | Standard Deviation 0.02 | LogMAR Score | |
| Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity | Group B: Dalfampridine | 2 | Standard Deviation 1 | letters | |
| Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity | Group B: Placebo | 2 | Standard Deviation 1 | letters | |
| Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity | Group A: Placebo | 4 | Standard Deviation 1 | letters | |
| Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity | Group A: Dalfampridine | 3 | Standard Deviation 1 | letters | |
| Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1 | Dalfampridine | 0.06 | Standard Deviation 0.02 | 5% Contrast LogMAR Score | |
| Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1 | Placebo | 0.05 | Standard Deviation 0.02 | 5% Contrast LogMAR Score | |
| Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart | Dalfampridine | 9.7 | 95% Confidence Interval 4.0 to 19.0 | Percentages of eyes that improved | |
| Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart | Placebo | 11.1 | 95% Confidence Interval 4.9 to 20.7 | Percentages of eyes that improved | |
| Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart | Both | 11.1 | 95% Confidence Interval 4.9 to 20.7 | Percentages of eyes that improved | |
| Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart | None | 68.1 | 95% Confidence Interval 56.0 to 78.6 | Percentages of eyes that improved | |
| Percentage of Eyes That Improved by One-line (5 Letters) | Dalfampridine | 11.1 | 95% Confidence Interval 4.9 to 20.7 | Percent of Eyes | |
| Percentage of Eyes That Improved by One-line (5 Letters) | Placebo | 15.3 | 95% Confidence Interval 7.9 to 25.7 | Percent of Eyes | |
| Percentage of Eyes That Improved by One-line (5 Letters) | Both | 37.5 | 95% Confidence Interval 26.4 to 49.7 | Percent of Eyes | |
| Percentage of Eyes That Improved by One-line (5 Letters) | Neither | 36.1 | 95% Confidence Interval 25.1 to 48.3 | Percent of Eyes | |
| Visual Evoked Potential P100 Latency Per Treatment Arm | Dalfampridine | 121.6 | Standard Deviation 2.4 | milliseconds | |
| Visual Evoked Potential P100 Latency Per Treatment Arm | Placebo | 120.2 | Standard Deviation 2.4 | milliseconds |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01337986/results